Oncology has long been pharma’s biggest bucket for R&D, with investment historically leading to some of pharma’s most impactful breakthroughs. Learn more in
this Trendline.
“This isn’t a podcast.”
That’s what Colorado Democratic Senator Michael Bennet threw at Robert F. Kennedy Jr. during a firework-strewn Senate hearing yesterday as he questioned the HHS secretary about a recent shakeup inside a CDC vaccine advisory committee. “This is the American people’s health that’s on the line here.”
Kennedy shot back: “You were never there complaining when the pharmaceutical companies were picking those [committees] and then running their products through with no safety testing,” he said, echoing a stance he held before he became the health secretary.
While lawmakers grilled Kennedy about a range of issues, including recent turmoil within the CDC, rising healthcare costs and PBMs, the questions kept pivoting back to vaccines.
After expressing concerns about how the new CDC committee could impact what Americans are told about getting shots, Bennet alleged that Kennedy’s “ideology” was creating “confusion” for the country.
The showdown highlighted the tension mounting around Kennedy as calls for his removal grow and even Republicans join the chorus of concern. Today, we’re looking closer at some of the key takeaways from the hearing and what’s at stake for vaccinemakers.
Robert F. Kennedy Jr. faced criticism Thursday even from Republican lawmakers over changes to federal vaccine policy as well as a leadership crisis at the CDC.
With so many unknowns surrounding regulatory and policy shifts, pharma companies might need to consider fundamental changes to how they operate, a Deloitte analyst said.
Rare diseases represent one of the most urgent and complex areas of opportunity in drug development. Explore how regulatory shifts, pricing challenges, and innovation are reshaping business strategies in
this Trendline.
The rundown from yesterday
Yesterday, we looked at how the EU and UK are aiming to lure American scientists onto their shores for work.
PharmaVoice readers who said that more drugs should be approved using the accelerated approval process, evenly split with those who said there should not be more.
Budget cuts are forcing pharma teams to rethink medical communications strategies for maximum impact. See how industry leaders are doing more with less in this infographic.
